JEFFREY M. JONAS - 28 Nov 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Jeffrey M. Jonas
Issuer symbol
SAGE
Transactions as of
28 Nov 2023
Net transactions value
-$75,827
Form type
4
Filing time
30 Nov 2023, 16:04:52 UTC
Previous filing
05 Sep 2023
Next filing
18 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SAGE Common Stock Award $0 +10,000 +8.2% $0.000000 131,981 28 Nov 2023 Direct F1
transaction SAGE Common Stock Tax liability $75,827 -3,935 -3% $19.27 128,046 28 Nov 2023 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 25, 2020, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 25,000 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on November 28, 2023, resulting in the vesting of the PSUs as to 10,000 shares.